Phase 3 (Enrollment)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: KarTX in Schizophrenia - Phase 3 Enrollment
ClinicalTrial.gov (NCT03697252): A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-1)
WHAT IS THE NEXT CATALYST EVENT?
Phase 3 Enrollment
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
11-2020: Corporate Update
MECHANISM OF ACTION
KarXT, a proprietary oral modulator of muscarinic cholinergic receptors, is Karuna’s lead product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an FDA-approved muscarinic antagonist that does not appreciably cross the blood-brain-barrier, to preferentially stimulate muscarinic receptors in the central nervous system (CNS). This novel product candidate, if approved, has the potential to usher in a new treatment paradigm and dramatically impact patients with schizophrenia and other psychotic disorders by providing a differentiated mechanism of action relative to current D2 dopamine and serotonin receptor-targeting antipsychotic drugs.
Across studies that use household-based survey samples, clinical diagnostic interviews, and medical records, estimates of the prevalence of schizophrenia and related psychotic disorders in the U.S. range between 0.25% and 0.64%.
Estimates of the international prevalence of schizophrenia among non-institutionalized persons is 0.33% to 0.75%.
Learn more at the National Institute of Mental Health
Updated by HC
KRTX, Schizophrenia, KarTX, mental health, mental disorder, brain, neurology,
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post